钠-葡萄糖协同转运蛋白2（SGLT2）抑制剂：基础与临床药理学综述
Sodium Glucose Co-Transporter-2 (SGLT2) Inhibitors: A Review of Their Basic and Clinical Pharmacology.
作者信息
Kalra Sanjay
机构信息
Bharti Hospital and B.R.I.D.E., Karnal, India,
出版信息
Diabetes Ther. 2014 Dec;5(2):355-66. doi: 10.1007/s13300-014-0089-4. Epub 2014 Nov 26.
Abstract
Sodium-glucose co-transporter-2 (SGLT2) inhibitors are a newly developed class of oral anti-diabetic drugs (OADs) with a unique mechanism of action. This review describes the biochemistry and physiology underlying the use of SGLT2 inhibitors, and their clinical pharmacology, including mechanism of action and posology. The pragmatic placement of these molecules in the existing OAD arena is also discussed.
摘要
钠-葡萄糖协同转运蛋白2（SGLT2）抑制剂是一类新开发的口服抗糖尿病药物（OADs），其作用机制独特。本综述描述了SGLT2抑制剂应用的生物化学和生理学基础，以及它们的临床药理学，包括作用机制和剂量学。还讨论了这些药物在现有口服抗糖尿病药物领域中的实际应用情况。
相似文献
1
Sodium Glucose Co-Transporter-2 (SGLT2) Inhibitors: A Review of Their Basic and Clinical Pharmacology.
Diabetes Ther. 2014 Dec;5(2):355-66. doi: 10.1007/s13300-014-0089-4. Epub 2014 Nov 26.
2
The Role of Sodium-Glucose Co-Transporter 2 Inhibitors in the Treatment of Type 2 Diabetes.
Clin Ther. 2015 Jun 1;37(6):1150-66. doi: 10.1016/j.clinthera.2015.03.004. Epub 2015 Apr 16.
3
Sodium glucose co-transporter 2 (SGLT2) inhibitors: new among antidiabetic drugs.
Cardiovasc Drugs Ther. 2014 Aug;28(4):331-4. doi: 10.1007/s10557-014-6522-0.
4
A Bioinformatics Investigation into the Pharmacological Mechanisms of Sodium-Glucose Co-transporter 2 Inhibitors in Diabetes Mellitus and Heart Failure Based on Network Pharmacology.
Cardiovasc Drugs Ther. 2022 Aug;36(4):713-726. doi: 10.1007/s10557-021-07186-y. Epub 2021 May 24.
5
Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus.
Drugs. 2015 Jan;75(1):33-59. doi: 10.1007/s40265-014-0337-y.
6
Sodium glucose co-transporter 2 inhibition reduces succinate levels in diabetic mice.
World J Gastroenterol. 2020 Jun 21;26(23):3225-3235. doi: 10.3748/wjg.v26.i23.3225.
7
Use of Sodium-Glucose Co-Transporter-2-Inhibitors (SGLT2-Is) and Risk of Lower Limb Amputation.
Curr Drug Saf. 2021;16(1):62-72. doi: 10.2174/1574886315666200805103053.
8
Infarct size, inflammatory burden, and admission hyperglycemia in diabetic patients with acute myocardial infarction treated with SGLT2-inhibitors: a multicenter international registry.
Cardiovasc Diabetol. 2022 May 15;21(1):77. doi: 10.1186/s12933-022-01506-8.
9
Susceptibility to serious skin and subcutaneous tissue disorders and skin tissue distribution of sodium-dependent glucose co-transporter type 2 (SGLT2) inhibitors.
Int J Med Sci. 2018 Jun 13;15(9):937-943. doi: 10.7150/ijms.22224. eCollection 2018.
10
Benefits and Harms of Sodium-Glucose Co-Transporter 2 Inhibitors in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis.
PLoS One. 2016 Nov 11;11(11):e0166125. doi: 10.1371/journal.pone.0166125. eCollection 2016.
引用本文的文献
1
Risk factors of urinary tract infections with sodium-glucose cotransporter-2 inhibitors in heart failure.
Medicine (Baltimore). 2025 Jul 11;104(28):e43245. doi: 10.1097/MD.0000000000043245.
2
Cardiorenal protection with dapagliflozin in patients with type 2 diabetes mellitus and chronic coronary syndrome undergoing percutaneous coronary intervention: a registry cross-sectional study.
Cardiovasc Diabetol. 2025 Apr 26;24(1):185. doi: 10.1186/s12933-025-02678-9.
3
Diabetes Mellitus and Associated Vascular Disease: Pathogenesis, Complications, and Evolving Treatments.
Adv Ther. 2025 Jun;42(6):2659-2678. doi: 10.1007/s12325-025-03185-9. Epub 2025 Apr 19.
4
Therapeutic management of PI3Kα inhibitor-induced hyperglycemia with a novel glucokinase activator: Advancing the Frontier of PI3Kα inhibitor therapy.
Mol Metab. 2025 Jun;96:102151. doi: 10.1016/j.molmet.2025.102151. Epub 2025 Apr 14.
5
Challenges, current innovations, and opportunities for managing type 2 diabetes in frail older adults: a position paper of the European Geriatric Medicine Society (EuGMS)-Special Interest Group in Diabetes.
Eur Geriatr Med. 2025 Feb 27. doi: 10.1007/s41999-025-01168-1.
6
Fixed dose combination of dapagliflozin, glimepiride and extended-release metformin tablets in patients with type 2 diabetes poorly controlled by metformin and glimepiride: A phase III, open label, randomized clinical study in India.
Diabetes Obes Metab. 2025 Apr;27(4):2193-2205. doi: 10.1111/dom.16218. Epub 2025 Feb 14.
7
SGLT2 Inhibitor Use in Chronic Kidney Disease: Supporting Cardiovascular, Kidney, and Metabolic Health.
Kidney Med. 2024 Jun 8;6(8):100851. doi: 10.1016/j.xkme.2024.100851. eCollection 2024 Aug.
8
Cutaneous Adverse Drug Reactions Associated with SGLT2 Inhibitors.
J Clin Med. 2024 Dec 31;14(1):188. doi: 10.3390/jcm14010188.
9
Hemodynamic Effects of SGLT2 Inhibitors in Patients with and Without Diabetes Mellitus-A Narrative Review.
Healthcare (Basel). 2024 Dec 6;12(23):2464. doi: 10.3390/healthcare12232464.
10
Arterial Hypertension: Novel Pharmacological Targets and Future Perspectives.
J Clin Med. 2024 Oct 4;13(19):5927. doi: 10.3390/jcm13195927.
本文引用的文献
1
Medication counselling with sodium glucose transporter 2 inhibitor therapy.
Indian J Endocrinol Metab. 2014 Sep;18(5):597-9. doi: 10.4103/2230-8210.139206.
2
Exploring the potential of the SGLT2 inhibitor dapagliflozin in type 1 diabetes: a randomized, double-blind, placebo-controlled pilot study.
Diabetes Care. 2015 Mar;38(3):412-9. doi: 10.2337/dc13-2955. Epub 2014 Sep 30.
3
Update on developments with SGLT2 inhibitors in the management of type 2 diabetes.
Drug Des Devel Ther. 2014 Sep 11;8:1335-80. doi: 10.2147/DDDT.S50773. eCollection 2014.
4
Canagliflozin provides durable glycemic improvements and body weight reduction over 104 weeks versus glimepiride in patients with type 2 diabetes on metformin: a randomized, double-blind, phase 3 study.
Diabetes Care. 2015 Mar;38(3):355-64. doi: 10.2337/dc13-2762. Epub 2014 Sep 9.
5
Sodium-glucose cotransporter 2 inhibition in type 1 diabetes: simultaneous glucose lowering and renal protection?
Can J Diabetes. 2014 Oct;38(5):356-63. doi: 10.1016/j.jcjd.2014.05.006. Epub 2014 Sep 3.
6
Pharmacodynamic effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, from a randomized study in patients with type 2 diabetes.
PLoS One. 2014 Aug 28;9(8):e105638. doi: 10.1371/journal.pone.0105638. eCollection 2014.
7
Safety profile of dapagliflozin for type 2 diabetes: pooled analysis of clinical studies for overall safety and rare events.
Drug Saf. 2014 Oct;37(10):815-29. doi: 10.1007/s40264-014-0213-4.
8
Durability of glycaemic efficacy over 2 years with dapagliflozin versus glipizide as add-on therapies in patients whose type 2 diabetes mellitus is inadequately controlled with metformin.
Diabetes Obes Metab. 2014 Nov;16(11):1111-20. doi: 10.1111/dom.12327. Epub 2014 Jul 10.
9
Renal sodium glucose cotransporter 2 inhibitors as a novel therapeutic approach to treatment of type 2 diabetes: Clinical data and mechanism of action.
J Diabetes Investig. 2014 May 4;5(3):265-75. doi: 10.1111/jdi.12214. Epub 2014 Apr 2.
10
Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production.
J Clin Invest. 2014 Feb;124(2):509-14. doi: 10.1172/JCI70704. Epub 2014 Jan 27.
Zotero 插件